Treatment with curcumin in CD44+/CD133+ human prostate cancer stem cells (HuPCaSCs) isolated from two pathologically different human PCa cell lines, 22RV1 and DU145, inhibits growth, invasion, and tumorigenicity of both non-stem prostate cancer cells and HuPCaSCs via targeting cell cycle arrest [161]. The gene discussed is CD44; the disease is prostate cancer.